Accelerating Rare disease Cures (ARC) Program Emerges as a Conduit for Empowering Rare Disease Stakeholders
The ARC Program strives to increase the number of treatments by promoting innovative scientific design, providing a deeper understanding of regulatory policies, and engaging with patients and their advocates, and other rare disease stakeholders.
Kerry Jo Lee Office Of Translational Sciences Office Of New Drugs Regulatory Aspects Of Rare Disease Drug Development Division Of Rare Diseases Rare Disease Drug Developers
Source: fda.gov